{
    "nctId": "NCT00612742",
    "briefTitle": "Safety and Efficacy of LibiGel\u00ae for Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women",
    "officialTitle": "A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Long-Term Safety and Efficacy of LibiGel\u00ae for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women",
    "overallStatus": "COMPLETED",
    "conditions": "Hypoactive Sexual Desire Disorder",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 3656,
    "primaryOutcomeMeasure": "The rate of adjudicated, predefined cardiovascular events in LibiGel-treated subjects compared to that of placebo-treated subjects.",
    "eligibilityCriteria": "Inclusion Criteria:\n\nPostmenopausal female subjects\n\n* at least 50 years of age\n* with at least two points of cardiovascular risk\n* with a clinical diagnosis of HSDD.\n\nExclusion Criteria:\n\nSubjects must not\n\n* require treatment with anti-androgens, high-dose oral or injectable corticosteroids, tamoxifen or other selective estrogen receptor modulators,\n* have used androgen therapy within 2 months of randomization,\n* have a history of estrogen-dependent neoplasia or any gynecologic cancer,\n* have a history of cancer of any kind in the past 10 years prior to randomization,\n* have a history of malignant melanoma or a history of invasive cancer at any time,\n* have a screening mammogram with any finding that requires follow up within 6 months of randomization,\n* have a history of myocardial infarction, coronary revascularization or stroke within 12 months of randomization,\n* have any medical condition associated with predicted survival of less than 3 years in the judgment of the Investigator.",
    "sex": "FEMALE",
    "minimumAge": "50 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}